Altogether, the above-mentioned findings suggest that it is potentially valuable to discover novel anti-inflammatory small-molecular drugs for IBD, focusing on transcriptomic signatures associated with GR and TET2. Here, NR3C1 is linked to inflammatory bowel disease.